Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis

Carolyn A. Foster, Laurence M. Howard, Alain Schweitzer, Elke Persohn, Peter C. Hiestand, Balázs Balatoni, Roland Reuschel, Christian Beerli, Manuela Schwartz and Andreas Billich
Journal of Pharmacology and Experimental Therapeutics November 2007, 323 (2) 469-475; DOI: https://doi.org/10.1124/jpet.107.127183
Carolyn A. Foster
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurence M. Howard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain Schweitzer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elke Persohn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter C. Hiestand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Balázs Balatoni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roland Reuschel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Beerli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuela Schwartz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Billich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

FTY720 [2-amino-2-[2-(4-octylphenyl) ethyl]propane-1,3-diol hydrochloride] is an oral sphingosine-1-phosphate receptor modulator under development for the treatment of multiple sclerosis (MS). The drug is phosphorylated in vivo by sphingosine kinase 2 to its bioactive form, FTY720-P. Although treatment with FTY720 is accompanied by a reduction of the peripheral lymphocyte count, its efficacy in MS and experimental autoimmune encephalomyelitis (EAE) may be due to additional, direct effects in the central nervous system (CNS). We now show that FTY720 localizes to the CNS white matter, preferentially along myelin sheaths. Brain trough levels of FTY720 and FTY720-P in rat EAE are of the same magnitude and dose dependently increase; they are in the range of 40 to 540 ng/g in the brain tissue at efficacious doses and exceed blood concentrations severalfold. In a rat model of chronic EAE, prolonged treatment with 0.03 mg/kg was efficacious, but limiting the dosing period failed to prevent EAE despite a significant decrease in blood lymphocytes. FTY720 effectiveness is likely due to a culmination of mechanisms involving reduction of autoreactive T cells, neuroprotective influence of FTY720-P in the CNS, and inhibition of inflammatory mediators in the brain.

Footnotes

  • This work was supported by Novartis Pharma AG.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.107.127183.

  • ABBREVIATIONS: FTY720, fingolimod, 2-amino-2-[2-(4-octylphenyl) ethyl]propane-1,3-diol hydrochloride; MS, multiple sclerosis; EAE, experimental autoimmune encephalomyelitis; SPHK, sphingosine kinase; CNS, central nervous system; DA, Dark Agouti; CFA, complete Freund's adjuvant; CsA, cyclosporine A; QWBA, quantitative whole-body autoradiography; CSF, cerebrospinal fluid; ANOVA, analysis of variance; AUC, area under the curve; FTY720-P, 2-amino-2-[2-(4-octylphenyl) ethyl) propane-1,3-diol-1-(dihydrogen phosphate); FK506, tacrolimus.

  • ↵1 Current affiliation: Novartis Hungary Healthcare, Budapest, Hungary.

  • ↵2 Current affiliation: Evangelisches Krankenhaus, Vienna, Austria.

    • Received June 24, 2007.
    • Accepted August 3, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 371 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 371, Issue 3
1 Dec 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
Citation Tools
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis

Carolyn A. Foster, Laurence M. Howard, Alain Schweitzer, Elke Persohn, Peter C. Hiestand, Balázs Balatoni, Roland Reuschel, Christian Beerli, Manuela Schwartz and Andreas Billich
Journal of Pharmacology and Experimental Therapeutics November 1, 2007, 323 (2) 469-475; DOI: https://doi.org/10.1124/jpet.107.127183

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis

Carolyn A. Foster, Laurence M. Howard, Alain Schweitzer, Elke Persohn, Peter C. Hiestand, Balázs Balatoni, Roland Reuschel, Christian Beerli, Manuela Schwartz and Andreas Billich
Journal of Pharmacology and Experimental Therapeutics November 1, 2007, 323 (2) 469-475; DOI: https://doi.org/10.1124/jpet.107.127183
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • All-trans retinoic acid inhibits migration and invasiveness of rheumatoid fibroblast-like synoviocytes
  • EP2/4 receptors promotes the synthesis of PGE2 increasing tissue damage in bovine endometrial explants induced by Escherichia coli
  • Role of RORγt in Interleukin-23–Mediated Skin Inflammation
Show more Inflammation, Immunopharmacology, and Asthma

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics